Rein Therapeutics (RNTX) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $8.00 | Aug 18, 2026 |
| Maxim Group | Initiated Coverage | Buy | $4.00 | Jul 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 from $10.00 | Jun 1, 2026 |
| Brookline Capital | Downgraded | Buy → Hold | — | Jan 21, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $10.00 | Sep 22, 2025 |
| Brookline Capital | Downgraded | Buy → Hold | — | Aug 19, 2025 |
| Ladenburg Thalmann | Maintained | Buy | $19.00 from $9.00 | Apr 18, 2024 |
| Ladenburg Thalmann | Upgraded | Neutral → Buy | $9.00 | Dec 1, 2023 |
Frequently asked questions
Is RNTX a buy, sell, or hold?
Analysts covering Rein Therapeutics currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on RNTX?
On Aug 18, 2026, HC Wainwright & Co. maintained Rein Therapeutics at Buy with a price target of $8.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.